Скачать или смотреть First RSV Vaccine Caps 60-Year Search to Stem Lung Illness

For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. The hunt is over.

The US Food and Drug Administration cleared GSK Plc’s shot against respiratory syncytial virus on Wednesday. The product will go on sale in the coming weeks for older adults.

Medical breakthroughs rarely come alone, and this one is no exception. GSK, seeking to reassert its role as a key vaccine industry player after falling behind in Covid-19, will likely be forced to battle it out with one of the biggest pandemic winners, Pfizer Inc., within weeks.

“This is certainly a revolution in preventative care,” said Emily Field, head of European pharmaceutical research at Barclays Plc. GSK already sells a blockbuster vaccine to protect older adults from shingles, and if they can repeat that success in RSV, “then they’ll be in a very good position,” Field said.

--------
Subscribe to our YouTube channel: https://bit.ly/2TwO8Gm
Subscribe to Bloomberg Originals:    / bloombergtv  

Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

Connect with us on…
YouTube:    / bloomberg  
Breaking News on YouTube:    / @bloombergquicktakenow  
Twitter:   / quicktake  
Facebook:   / quicktake  
Instagram:   / quicktake